CAPLIPOINT2,792.00

Caplin Point Laboratories Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMERISGLANDBLUEJETCONCORDBIOACUTAASEMCUREGRANULESMcap ₹21,219 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)552.56493.77438.22438.22
Receivable Days (DSO)116.93119.15137.81137.81
Payable Days (DPO)318.75319.65302.49276.52
Cash Conversion Cycle (days)350.74293.27273.54299.51
Working Capital Turnover1.081.060.991.04
Asset Turnover0.630.600.540.54
Cash Conversion (CFO/Net Income)0.670.800.810.81
CFO/EBITDA0.560.670.690.69
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.